Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only Get Premium

INMB Inmune Bio Inc

Price (delayed)

$7.86

Market cap

$182.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.93

Enterprise value

$163.44M

INmune Bio, Inc. is a publicly traded, clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease. INmune Bio has two product platforms. The ...

Highlights
The debt has dropped by 96% year-on-year and by 10% since the previous quarter
The EPS has increased by 9% since the previous quarter
INMB's quick ratio has soared by 64% YoY but it is down by 16% QoQ
Inmune Bio's net income has decreased by 18% YoY but it has increased by 3.1% QoQ
The gross profit has shrunk by 62% YoY
The revenue has dropped by 62% year-on-year

Key stats

What are the main financial stats of INMB
Market
Shares outstanding
23.21M
Market cap
$182.43M
Enterprise value
$163.44M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
6.07
Price to sales (P/S)
3,536.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,268.87
Earnings
Revenue
$50,000
Gross profit
$50,000
Operating income
-$41.52M
Net income
-$40.8M
EBIT
-$40.8M
EBITDA
-$40.8M
Free cash flow
-$32.71M
Per share
EPS
-$1.93
EPS diluted
-$1.93
Free cash flow per share
-$1.45
Book value per share
$1.29
Revenue per share
$0
TBVPS
$0.95
Balance sheet
Total assets
$37.8M
Total liabilities
$8.13M
Debt
$347,000
Equity
$29.67M
Working capital
$13.03M
Liquidity
Debt to equity
0.01
Current ratio
2.64
Quick ratio
2.44
Net debt/EBITDA
0.47
Margins
EBITDA margin
-81,592%
Gross margin
100%
Net margin
-81,592%
Operating margin
-83,046%
Efficiency
Return on assets
-89.4%
Return on equity
-119.4%
Return on invested capital
N/A
Return on capital employed
-136.6%
Return on sales
-81,592%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INMB stock price

How has the Inmune Bio stock price performed over time
Intraday
7.82%
1 week
12.77%
1 month
7.52%
1 year
-29.63%
YTD
68.31%
QTD
0.64%

Financial performance

How have Inmune Bio's revenue and profit performed over time
Revenue
$50,000
Gross profit
$50,000
Operating income
-$41.52M
Net income
-$40.8M
Gross margin
100%
Net margin
-81,592%
The net margin has surged by 73% since the previous quarter
The operating margin has soared by 73% QoQ
The gross profit has shrunk by 62% YoY
The revenue has dropped by 62% year-on-year

Price vs fundamentals

How does INMB's price correlate with its fundamentals

Growth

What is Inmune Bio's growth rate over time

Valuation

What is Inmune Bio stock price valuation
P/E
N/A
P/B
6.07
P/S
3,536.4
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3,268.87
The EPS has increased by 9% since the previous quarter
The P/B is 69% higher than the 5-year quarterly average of 3.6 and 45% higher than the last 4 quarters average of 4.2
INMB's equity is down by 8% since the previous quarter but it is up by 5% year-on-year
The revenue has dropped by 62% year-on-year
The price to sales (P/S) is 21% lower than the 5-year quarterly average of 4493.8 and 4.2% lower than the last 4 quarters average of 3690.2

Efficiency

How efficient is Inmune Bio business performance
The ROS has soared by 73% since the previous quarter
INMB's ROA has shrunk by 53% YoY
Inmune Bio's ROE has decreased by 39% YoY but it has increased by 4% from the previous quarter

Dividends

What is INMB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INMB.

Financial health

How did Inmune Bio financials performed over time
INMB's quick ratio has soared by 64% YoY but it is down by 16% QoQ
The total liabilities has shrunk by 54% YoY but it rose by 9% QoQ
The debt is 99% smaller than the equity
The debt to equity has dropped by 96% year-on-year
The debt has dropped by 96% year-on-year and by 10% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.